This review summarises selected literature published from January 2013 to November 2016 on the use of the live attenuated varicella-zoster virus vaccine for the prevention of herpes zoster in adults from 50 years of age.

The focus of this review will be on the currently licensed live attenuated zoster vaccine. However, clinical trial data for the adjuvanted subunit zoster vaccine will be reviewed briefly, since regulatory approval is being sought for this vaccine and it is expected to be licensed during 2017.